🦊/Companies

CUREosity

Düsseldorf, DE · 1 known investors

Find your way into CUREosity

192 people in our graph share verified history with the CUREosity team — schools, employers, funds. One of them is your warm intro.

Javier Mataunlockedknows Stefan Arand · together at Freelancer (overlapped)
×2knows the team · via Freelancer
knows the team · via Heise Zeitschriften Verlag GmbH & Co. KG
×2knows the team · via Bergische Universität Wuppertal
×6knows the team · via The University of Freiburg

CUREOSITY develops CUREO, a virtual reality therapy system used in rehabilitation institutions to treat patients with motorsensory and cognitive impairments. The company serves clinics and practices, primarily in Germany but also globally, within the digital health and medtech sector.

Founders & leadership

TSThomas Saur
Thomas SaurinThomas Saur has spent over 20 years conducting research in neurophysiology, focusing on brain plasticity, sensory information processing, and the relationship between body awareness and physiological processes. He founded CUREosity to develop therapeutic concepts based on these research areas.
SAStefan Arand
Stefan ArandinHe previously spent 20 years in a leadership role at TSAMEDIEN Arand & Saur.
MFMarco Faulhammer
Marco FaulhammerinFounder

Investors · 1

Competitors · 5

by search overlap

Companies competing with CUREosity for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does CUREosity do?
CUREOSITY develops CUREO, a virtual reality therapy system used in rehabilitation institutions to treat patients with motorsensory and cognitive impairments. The company serves clinics and practices, primarily in Germany but also globally, within the digital health and medtech sector.
Who founded CUREosity?
CUREosity was founded by Thomas Saur, Stefan Arand, Marco Faulhammer.
Who are CUREosity's investors?
CUREosity's investors include TechVision Fonds.
Where is CUREosity headquartered?
CUREosity is headquartered in Düsseldorf, DE.